共 74 条
[1]
Argyriou AA(2012)Chemotherapy-induced peripheral neurotoxicity (CIPN): an update Crit Rev Oncol Hematol 82 51-77
[2]
Bruna J(2014)Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis Pain 155 2461-2470
[3]
Marmiroli P(2020)Drug repositioning for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a mechanism- and screening-based strategy Front Pharmacol 11 897-902
[4]
Seretny M(2020)Effects of the publication of Clinical Guidelines for the Management of Chemotherapy-Induced Peripheral Neuropathy on the Administration Preferences of Oncology Specialists: Japanese Association of Supportive Care in Cancer Jpn J Clin Oncol 50 3325-3348
[5]
Currie GL(2020)Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update J Clin Oncol 38 1306-1319
[6]
Sena ES(2020)Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up Ann Oncol 31 708-716
[7]
Yamamoto S(2011)Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility Oncologist 16 413-419
[8]
Egashira N(2010)Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage J Epidemiol 20 118-127
[9]
Hirayama Y(2021)Data resource profile: JMDC claims database sourced from health insurance societies J Gen Fam Med 22 3109-3116
[10]
Yoshida Y(2009)Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 1465-1471